Abstract
In the context of the ongoing SARS-CoV-2 pandemic, health officials warn that vaccines must be uniformly distributed within and among countries if we are to quell the pandemic. Yet there has been little critical assessment of the underlying reasons for this warning. Here, we explicitly show why vaccine equity is necessary. We begin by drawing an analogy to studies showing how disparities in drug concentration within a single host can promote the evolution of drug resistance, and we then proceed to mathematical modeling and simulation of vaccine escape evolution in structured host populations. Perhaps counter-intuitively, we find that vaccine escape mutants are less likely to come from vaccinated regions where there is strong selection pressure for vaccine escape and more likely to come from a neighboring unvaccinated region where there is no selection for escape. Unvaccinated geographic regions thus provide evolutionary reservoirs from which vaccine escape mutants can arise and infect neighboring vaccinated regions, causing new local epidemics within those regions and beyond. Our findings have timely implications for vaccine rollout strategies and public health policy.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
P.G. and A.C. received financial support from the USA/Brazil Fulbright scholar program. J.V. and F.S. received financial suppot from grants DGAPA-PAPIIT UNAM IV100220 and DGAPA-PAPIIT IN115720 UNAM.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
no IRB or ethics committee approvals were necessary for this work.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Computer code for simulations is freely available upon request to the corresponding author.
